Status: Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).
Participants needed: 44
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Aug 19, 2026Locations: 17
Eligibility criteria
Signed informed consent must be obtained prior to participation in the study. [+5]
Participants who have a familial/hereditary form (e.g. familial cold autoinflamm... [+36]